Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 5.43%
As of Friday, September 11, Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Commentary & Analysis
Which Is a Better Investment, Arcus Biosciences, Inc. or Xencor, Inc. Stock?
Learn more about whether Arcus Biosciences, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
What You Need to Know About Arcus Biosciences, Inc.'s Q3 Earnings
Arcus Biosciences, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (RCUS) missed or beat analyst's expectations.Tudor Pop
Which Is a Better Investment, CareDx, Inc. or Arcus Biosciences, Inc. Stock?
Learn more about whether CareDx, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Is Arcus Biosciences, Inc. (RCUS) Overvalued?
We dive into why Arcus Biosciences, Inc. (RCUS) could be considered overvalued on 2026-07-31, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,096.7 | $262.9 | 60% |
|
| Shares Out (Mil) | 126.1 | 54.4 | 67% |
|
| Institutional Ownership | 95.3% | 92.9% | 67% |
|
| Float (Mil) | 90.5 | 41.5 | 59% |
|
| Beta | 0.81 | 0.94 | 48% |
|
| Avg Daily Volume (000s) | 1,769 | 496 | 81% |
|
| Price Change (52-week) |
111.1% | 54.5% | 94% |
|
| Growth | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 25.9% | 14.1% | 87% |
|
| Net Income (5yr) | (23.5%) | (10.1%) | 17% |
|
| EPS (5yr) | (7.9%) | 15.8% | 23 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.6%) | (15.6%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.881) | ($3.526) | ($3.340) | |
| Month Ago EPS | ($0.913) | ($3.648) | ($3.253) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.826) | ($3.483) | ($3.103) | |
| Year/Year Chg | 22.0% | 7.3% | (15.2%) | |
| Financials | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $117 | $37 | 27% |
|
| Net Income (TTM) (Mil) | ($460) | ($43) | 3% |
|
| EPS (TTM) | ($3.862) | ($1.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($474) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($98) | $2 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $225 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $3,026 | $179 | 54% |
|
| Valuation | RCUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.66 | 2.56 | 85% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (324.8%) | 68.2% | 1% |
|
| Net Margin | (393.2%) | (73.0%) | 3% |
|
| ROA | (46.0%) | (47.9%) | 12% |
|
| ROE | (90.8%) | (55.0%) | 10% |
|
| Liabilities to Assets | 49.8% | 29.4% | 42% |
|
| F-Score | 0 | 2 | na |
|
Arcus Biosciences, Inc. did not pass any screens on 9/14/2026.
